Abstract 702P
Background
Human leukocyte antigens (HLAs) are expressed in a variety of cells, including cancer cells and immune cells. Recent studies have shown that germline HLA gene zygosity, supertype and individual HLA genotypes may be associated with immunotherapy (IO) outcomes. We aimed to evaluate whether germline HLA-A gene haplotype and zygosity is associated with response to IO.
Methods
Pts enrolled in phase 1 clinical trials in the Vall d´Hebron Institute of Oncology Early Drug Development Unit with available HLA-A testing were reviewed. Median progression free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.
Results
From 2021 to 2023 a total of 247 eligible pts were reviewed. Median age was 59y, 63% female, main types of tumor with positive HLA biomarker were colorectal/anal cancer 19% (47pts), gynecological tumors 14%(34pts); and breast cancer 14% (34pts). Alleles present at >5% samples: 02:01:01 25%, 01:01:01 11%, 03:01:01 11%, 24:02:01 9%, 29:02:01 8%. Twenty-five (10.20%) pts presented HLA-A homozygosis. Homozygosis occurred in the most common haplotypes: 02:01:01 (14pts), 01:01:01 (2pts), 03:01:01 (4pts%), 24:02:01 (2pts%) and 29:02:01 (2pts). Eighty-five (34.5%) pts received IO; main types of tumors that received IO were genitourinary tumors 67% (10pts), gynecological tumors 45% (16pts) and colorectal/anal tumors 27% (13pts). Pts treated with anti-PD1 were 17 (20%), anti-PDL1 17 (20%) and other combinations 20 (24%). Twelve patients (17%) had PR, and thirty eight (45%) SD. Overal PFS and OS was 6.1 months and 29.6 months respectively. Presence of 03:01:01 was associated with a higher likelihood of response. Six pts with HLA homozygosis received inmunotherapy, all of them achieved SD as best response (NS).
Conclusions
Prevalence of HLA 02:01:01 in our population is significantly lower than reported in other populations. Presence of Homozygoses was not significantly associated with lack of response to inmunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research has been funded by CaixaResearch Advanced Oncology Research Program supported by Fundació La Caixa, by the Comprehensive Program of Cancer Immunotherapy & Immunology II (CAIMI-II) supported by the BBVA Foundation (grant 53/2021).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
107P - Comprehensive genomic profiling of “The German-registry of incidental gallbladder carcinoma” cases
Presenter: Nihat Bugra Agaoglu
Session: Poster session 17
108P - FGFR2 fusions and their impact on efficacy of standard chemotherapy in patients with biliary tract cancer
Presenter: Binbin Zheng-Lin
Session: Poster session 17
109P - DNA damage repair pathways in biliary tract cancer: A new target for precision medicine?
Presenter: Ilektra Mavroeidi
Session: Poster session 17
110P - Detection of HER2 overexpression in biliary tract cancers: Comparison of AmoyDx® HER-2 (29D8) assay with ventana PATHWAY anti-HER-2/neu (4B5) assay
Presenter: Hui Dong
Session: Poster session 17
111P - The concordance between circulating tumor DNA and tissue genomic profiling in patients with advanced biliary tract cancer
Presenter: Seonjeong Woo
Session: Poster session 17
112P - Clinical, genomic and transcriptomic characteristics of young-onset biliary tract cancers
Presenter: Thomas Pudlarz
Session: Poster session 17
113P - Molecular profiling of biliary tract cancers in patients of African and European ancestries
Presenter: Zishuo Hu
Session: Poster session 17
114P - Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers
Presenter: Gentry King
Session: Poster session 17
115P - Inhibition of KLF5 reduces tumor growth and sensitizes to chemotherapy-induced cell death in experimental models of cholangiocarcinoma
Presenter: Ana Landa Magdalena
Session: Poster session 17